B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-03-04Clinical Trial Update: A Study of XS-04 in Patients with Relapsed or Refractory Hematologic Malignancies [Phase 1]
Phase 1 study of XS-04 in relapsed or refractory hematologic malignancies, including B-cell lymphoma, acute myeloid leukemia, and myelodyspl…
-
CLINICAL_TRIALS research · 2025-02-27Clinical Trial Update: CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma [NA]
A CD30-targeted CAR-T therapy is being studied for CD30-positive relapsed/refractory lymphoma. The trial is currently recruiting.
-
CLINICAL_TRIALS research · 2025-02-19Clinical Trial Update: CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating CAR2219 CAR-T cells for relapsed or refractory B-cell leukemia and B-cell lymphoma is currently recrui…
-
CLINICAL_TRIALS research · 2025-02-19Clinical Trial Update: Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma [Phase 2]
Phase 2 clinical trial evaluating chidamide in combination with linperlisib for refractory/relapsed follicular lymphoma is currently recruit…
-
CLINICAL_TRIALS research · 2025-01-13Clinical Trial Update: Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia [Phase 2]
Phase 2 clinical trial update on locally manufactured CAR T-cell products for multiple B-cell malignancies, including B-cell lymphoma and B-…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-01-06Clinical Trial Update: Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies [Phase 1]
A Phase 1 clinical trial evaluating safety and efficacy of a fourth-generation CAR-T therapy for hematologic malignancies, including multipl…
-
CLINICAL_TRIALS research · 2024-12-16Clinical Trial Update: CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors [Phase 1, Phase 2]
A Phase 1/2 trial evaluating CD19 and CD22 bispecific CAR T cells for relapsed/refractory B-cell hematologic tumors, currently recruiting.
-
CLINICAL_TRIALS research · 2024-11-20Clinical Trial Update: A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma [Phase 2]
A Phase 2 clinical study evaluating TQB3702 tablets with immunochemotherapy for B-cell lymphoma is currently recruiting.
-
CLINICAL_TRIALS research · 2024-09-26Clinical Trial Update: A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor [Phase 1]
This clinical trial update notes a Phase 1 study of the investigational therapy HDM2005 in patients with relapsed or refractory B-cell lymph…
-
CLINICAL_TRIALS research · 2024-08-22Clinical Trial Update: JWCAR201 for the Treatment of Hematology Malignancy and Autoimmune Diseases [Phase 1]
This clinical trial update outlines the Phase 1 study JWCAR201 for hematology malignancies and autoimmune diseases, which is currently not r…
-
CLINICAL_TRIALS research · 2024-07-17Clinical Trial Update: Incidence and Risks Factors of CMV Reactivation in Patients Receiving of CAR-T Cells for Acute Leukemia and Lymphoma Relapse, a Cohort Study Analysis
A cohort-study analysis evaluating the incidence and risk factors of CMV reactivation in patients receiving CAR-T cell therapy for relapse o…
-
CLINICAL_TRIALS research · 2024-06-07Clinical Trial Update: Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma [Phase 1]
Phase 1 clinical trial evaluating ISM8207 in participants with advanced solid tumors or relapsed/refractory B-cell lymphoma, currently recru…
-
CLINICAL_TRIALS research · 2024-06-06Clinical Trial Update: CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL [Phase 1]
Phase 1 study of CD19/CD22 CAR-T cells in adults with relapsed or refractory acute lymphoblastic leukemia or B-cell lymphoma, currently recr…
-
CLINICAL_TRIALS research · 2024-05-16Clinical Trial Update: Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell Lymphoma [Phase 2]
Phase 2 clinical trial evaluating obinutuzumab in combination with bendamustine for mature B-cell lymphoma; currently recruiting in China.
-
CLINICAL_TRIALS research · 2024-05-09Clinical Trial Update: CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study) [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating CAR20(NAP)-T therapy for B-cell lymphoma is currently recruiting.
-
CLINICAL_TRIALS research · 2019-01-31Clinical Trial Update: Study of Anti-CD19 iCAR NK Cells in Relapsed and Refractory B Cell Lymphoma [EARLY_Phase 1]
An early-phase 1 study evaluating anti-CD19 iCAR NK cells for relapsed and refractory B-cell lymphoma. The current sponsor-reported status i…
-
CLINICAL_TRIALS research · 2019-01-31Clinical Trial Update: Study of Anti-CD19/CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma [EARLY_Phase 1]
An early-phase 1 clinical trial is evaluating anti-CD19/CD22 CAR NK cells in relapsed and refractory B-cell lymphoma; the current status is …
-
CLINICAL_TRIALS research · 2019-01-30Clinical Trial Update: Study of Anti-CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma [EARLY_Phase 1]
An early-phase (Phase 1) clinical trial investigating anti-CD22 CAR NK cells for relapsed and refractory B-cell lymphoma; the study status i…
-
CLINICAL_TRIALS research · 2018-07-02Clinical Trial Update: CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation [NA]
This clinical trial update discusses a CD19-targeted CAR-T cell therapy approach for minimal residual disease–positive B-cell lymphoma or le…
-
CLINICAL_TRIALS research · 2018-05-30Clinical Trial Update: Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma [Phase 1]
Phase 1 clinical trial update on Cytoplasmic Activated PD-1 CAR T Cells for relapsed/refractory B-cell non-Hodgkin lymphoma.
-
CLINICAL_TRIALS research · 2017-07-02Clinical Trial Update: Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell Lymphoma [Phase 1, Phase 2]
Phase 1/2 study assessing sequential infusion of CD19- and CD20-directed CAR-T cells in relapsed or refractory B-cell lymphoma.
-
CLINICAL_TRIALS research · 2017-06-23Clinical Trial Update: A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma [Phase 1, Phase 2]
Clinical trial update on UCART019 for relapsed/refractory CD19+ leukemia and lymphoma (Phase 1/2) conducted by Chinese PLA General Hospital.
-
CLINICAL_TRIALS research · 2017-04-28Clinical Trial Update: CAR T Cells for Refractory B Cell Malignancy [Phase 1, Phase 2]
This entry reports an ongoing Phase 1/Phase 2 trial of CAR T cell therapy for refractory B-cell malignancies, including B-cell leukemia and …
-
CLINICAL_TRIALS research · 2016-11-16Clinical Trial Update: Pilot Study of Anti-CD20-CAR-engineered T Cells in Patients With Chemotherapy Resistant or Refractory CD20+ Lymphoma [Phase 1, Phase 2]
Pilot Phase 1/2 clinical trial evaluating anti-CD20 CAR-T cells in patients with chemotherapy-resistant or refractory B-cell lymphoma. The t…
-
CLINICAL_TRIALS research · 2016-06-28Clinical Trial Update: Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies [NA]
Clinical trial update regarding Chimeric Antigen Receptor T Cells (CART) therapy for refractory/relapsed B-cell hematologic malignancies.